Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21300977)

1.

Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders.

Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA.

Blood. 2011 Apr 21;117(16):4315-22. doi: 10.1182/blood-2010-11-320481. Epub 2011 Feb 7.

3.

EBV LMP2A affects LMP1-mediated NF-kappaB signaling and survival of lymphoma cells by regulating TRAF2 expression.

Guasparri I, Bubman D, Cesarman E.

Blood. 2008 Apr 1;111(7):3813-20. doi: 10.1182/blood-2007-03-080309. Epub 2008 Jan 29. Erratum in: Blood. 2008 Jul 15;112(2):452.

4.

Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation.

Chou YC, Lin SJ, Lu J, Yeh TH, Chen CL, Weng PL, Lin JH, Yao M, Tsai CH.

Blood. 2011 Aug 4;118(5):1340-9. doi: 10.1182/blood-2011-02-335448. Epub 2011 Jun 9.

5.

Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.

Popescu I, Macedo C, Zeevi A, Nellis J, Patterson KR, Logar A, Rowe D, Reyes J, Rao AS, Storkus WJ, Fung JJ, Metes D.

Am J Transplant. 2003 Nov;3(11):1369-77.

6.

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA.

J Natl Cancer Inst. 2004 Oct 6;96(19):1447-57.

7.

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA.

Clin Cancer Res. 2012 Mar 15;18(6):1611-8. doi: 10.1158/1078-0432.CCR-11-1942. Epub 2012 Jan 23. Erratum in: Clin Cancer Res. 2012 Apr 1;18(7):2117.

8.

EBV transformation overrides gene expression patterns of B cell differentiation stages.

Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Küppers R.

Mol Immunol. 2008 Jun;45(11):3133-41. doi: 10.1016/j.molimm.2008.03.002. Epub 2008 Apr 21.

PMID:
18430472
10.

Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.

Rea D, Fourcade C, Leblond V, Rowe M, Joab I, Edelman L, Bitker MO, Gandjbakhch I, Suberbielle C, Farcet JP, et al.

Transplantation. 1994 Aug 15;58(3):317-24.

PMID:
8053055
11.

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.

Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Viganò M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R.

Blood. 2002 Apr 1;99(7):2592-8.

13.

EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.

Le Clorennec C, Youlyouz-Marfak I, Adriaenssens E, Coll J, Bornkamm GW, Feuillard J.

Blood. 2006 Mar 1;107(5):2070-8. Epub 2005 Nov 29.

14.

Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.

Vrazo AC, Chauchard M, Raab-Traub N, Longnecker R.

PLoS Pathog. 2012;8(4):e1002662. doi: 10.1371/journal.ppat.1002662. Epub 2012 Apr 19.

15.
16.

In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).

Rochford R, Miller CL, Cannon MJ, Izumi KM, Kieff E, Longnecker R.

Arch Virol. 1997;142(4):707-20.

PMID:
9170499
17.

Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas.

Murray PG, Swinnen LJ, Flavell JR, Ragni MV, Baumforth KR, Toomey SM, Filipovich AH, Lowe D, Schnell CS, Johl J, Gulley M, Young LS, Ambinder RF.

Hum Pathol. 2001 Sep;32(9):963-9.

PMID:
11567226
18.

The role of Epstein-Barr virus in neoplastic transformation.

Knecht H, Berger C, Rothenberger S, Odermatt BF, Brousset P.

Oncology. 2001;60(4):289-302. Review.

PMID:
11408795
19.

In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.

Pioche-Durieu C, Keryer C, Souquère S, Bosq J, Faigle W, Loew D, Hirashima M, Nishi N, Middeldorp J, Busson P.

J Virol. 2005 Nov;79(21):13326-37.

20.

The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein-Barr virus.

Kutz H, Reisbach G, Schultheiss U, Kieser A.

Virology. 2008 Feb 20;371(2):246-56. Epub 2007 Oct 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk